AU2021375735A1 - A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections - Google Patents

A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections Download PDF

Info

Publication number
AU2021375735A1
AU2021375735A1 AU2021375735A AU2021375735A AU2021375735A1 AU 2021375735 A1 AU2021375735 A1 AU 2021375735A1 AU 2021375735 A AU2021375735 A AU 2021375735A AU 2021375735 A AU2021375735 A AU 2021375735A AU 2021375735 A1 AU2021375735 A1 AU 2021375735A1
Authority
AU
Australia
Prior art keywords
aat
pharmaceutical composition
mscs
extra
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021375735A
Other languages
English (en)
Other versions
AU2021375735A9 (en
Inventor
Manfred Stangl
Michael Strassmair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aatec Medical GmbH
Original Assignee
Aatec Medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20206287.3A external-priority patent/EP3995130A1/en
Application filed by Aatec Medical GmbH filed Critical Aatec Medical GmbH
Publication of AU2021375735A1 publication Critical patent/AU2021375735A1/en
Publication of AU2021375735A9 publication Critical patent/AU2021375735A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021375735A 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections Abandoned AU2021375735A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20206287.3 2020-11-06
EP20206287.3A EP3995130A1 (en) 2020-11-06 2020-11-06 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP21159620 2021-02-26
EP21159620.0 2021-02-26
PCT/EP2021/080936 WO2022096708A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Publications (2)

Publication Number Publication Date
AU2021375735A1 true AU2021375735A1 (en) 2023-06-08
AU2021375735A9 AU2021375735A9 (en) 2024-09-05

Family

ID=78806458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021375735A Abandoned AU2021375735A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Country Status (7)

Country Link
US (1) US20230414730A1 (https=)
EP (1) EP4240323A1 (https=)
JP (1) JP2023547728A (https=)
AU (1) AU2021375735A1 (https=)
CA (1) CA3200691A1 (https=)
IL (1) IL302649A (https=)
WO (1) WO2022096708A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN115381857B (zh) * 2022-10-28 2023-02-03 上海市东方医院（同济大学附属东方医院） 间充质干细胞在制备治疗hpv持续感染的药物中的应用
EP4680254A1 (en) * 2023-03-17 2026-01-21 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025227013A1 (en) * 2024-04-26 2025-10-30 Musc Foundation For Research Development Extracellular vesicles from alpha-1 antitrypsin overexpressing cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
EP1366175B1 (en) * 2000-12-18 2008-01-23 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP2148693A4 (en) * 2007-04-20 2010-06-02 Univ Colorado ALPHA-I-ANTITRYPINE WITHOUT SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITY
RU2539099C2 (ru) 2009-04-13 2015-01-10 Апцет Гмбх Унд Ко.Кг Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
US9901600B2 (en) * 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Also Published As

Publication number Publication date
JP2023547728A (ja) 2023-11-13
AU2021375735A9 (en) 2024-09-05
CA3200691A1 (en) 2022-05-12
US20230414730A1 (en) 2023-12-28
EP4240323A1 (en) 2023-09-13
IL302649A (en) 2023-07-01
WO2022096708A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
US20230414730A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
Pocsfalvi et al. COVID-19 and extracellular vesicles: an intriguing interplay
US6271206B1 (en) Sonic nebulized nucleic acid/cationic liposome complexes and methods for pulmonary gene delivery
TW202334430A (zh) 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染
FR2711523A1 (fr) Procédé de préparation d'un aérosol viral.
WO2019046664A1 (en) COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS
CA3132564A1 (en) Process for making stable bacterial extracts and their use as pharmaceuticals
US20260116934A1 (en) Compositions and Methods for Delivering CFTR Polypeptides
CN116710118A (zh) 病毒性呼吸道感染的治疗方法
KR20220134764A (ko) 염증성 폐 질환의 흡입식 치료를 위한 인간 항염증성 펩타이드
US20210189427A1 (en) Compositions and methods for gene delivery to the airways and/or lungs
EP3995130A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
US12433960B2 (en) Vivo gene therapy using intraosseous delivery of a lentiviralgene construct
JP2001503401A (ja) 直接タンパク質送達することが困難な領域での遺伝子送達及び発現
US20130064792A1 (en) Therapy for influenza like illness
CA2612646C (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
RU2770364C1 (ru) Способ лечения болезней легких ингаляционным введением мезенхимальных стромальных клеток и гексапептида
Zhang et al. Adipose-derived mesenchymal stem cells suppress ozone-mediated airway inflammation in a mouse model of chronic obstructive pulmonary disease
CN116033903A (zh) 奎宁及其产生先天免疫应答的用途
CN118434880A (zh) 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途
HK1114567B (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period